Published in Blood Weekly, March 20th, 2008
Under the terms of the agreement, Vermillion is granted exclusive rights to the biomarker panel, and will undertake the development and commercialization of a PAD blood test,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.